Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Phyto-N
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Dominari Securities
Deal Size : $15.0 million
Deal Type : Public Offering
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
Details : The Company intends to use the proceeds from the Offering for the development of its lead product candidate, Phyto-N, for the treatment of ulcerative colitis.
Product Name : Phyto-N
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
August 26, 2025
Lead Product(s) : Phyto-N
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Dominari Securities
Deal Size : $15.0 million
Deal Type : Public Offering
Reset All
